Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludrocortisone acetate for geographic atrophy secondary to age-related macular degeneration (Part B)
ACTRN12624000997550Phase 2Not yet recruiting
- Sponsor
- Eye Co
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fludrocortisone in age-related macular degeneration (AMD) (2 arms), sponsored by Eye Co. Primary endpoint: Efficacy on geographic atrophy progression. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
fludrocortisone
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ACTRN12624000997550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000997550.